Impact of obesity on clinical outcomes in patients treated with ceftobiprole: results from Phase 3 clinical trials.

ABSTRACT:

Background

Ceftobiprole was non-inferior to comparators for the treatment of Staphylococcus aureus bloodstream infection (bacteraemia) (SAB), acute bacterial skin and skin structure infection (ABSSSI), and community-acquired bacterial pneumonia (CABP), leading to regulatory approval for these indications. Whether dosing should be modified for patients with obesity is unknown.

Objectives

This post hoc analysis evaluated the relationship of obesity and clinical outcomes in patients treated with ceftobiprole for SAB, ABSSSI or CABP.

Methods

Efficacy and safety outcomes were assessed based on BMI from three registrational clinical trials that evaluated ceftobiprole against comparators.

Results

Overall, 1641 patients were included from the three Phase 3 clinical tri

SUBMITTER: Holland TL 

PROVIDER: S-EPMC12129573 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature